Scientific publications
At Day One, we use the power of leading-edge science to improve patient outcomes.
We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
April 2024
Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records
Disease burden and healthcare utilization in pediatric low-grade glioma: a United States retrospective study of linked claims and electronic health records [published online ahead of print April 27, 2024]. Neuro-Oncol Pract. 2024.
April 2024
Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation
1972. Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation. Poster presentation at: AACR (American Association for Cancer Research) Annual Meeting 2024; April 8, 2023; San Diego, CA.
April 2024
Clinical activity and safety of tovorafenib in patients with optic pathway gliomas in FIREFLY-1
902. Clinical Activity and Safety of Tovorafenib in Patients with Optic Pathway Gliomas in FIREFLY-1. Poster presentation at: 2024 ASPHO (American Society of Pediatric Hematology/Oncology); April 4 & 5, 2024; Seattle, WA.
Jan 2024
A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration [published online ahead of print January 30, 2024]. BMC Cancer. 2024.
Nov 2023
Clinical activity of RAF inhibitor tovorafenib according to prior MAPK inhibitor treatment in the registrational low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study
CTNI-37. Clinical activity of RAF inhibitor tovorafenib according to prior MAPK inhibitor treatment in the registrational low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. Oral presentation at: 28th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 17, 2023, Vancouver, Canada.
Nov 2023
Clinical activity and safety of the RAF inhibitor tovorafenib in patients with optic pathway gliomas in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study
CTNI-24. Clinical activity and safety of the RAF inhibitor tovorafenib in patients with optic pathway gliomas in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. Presentation at: 28th Annual Meeting and Education Day of the Society for Neuro-Oncology, November 17, 2023, Vancouver, Canada.